Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression
Peter Reinhardt(AbbVie (United States)), Jared Sterneckert(University Hospital Carl Gustav Carus), Kathrin Brockmann(Oregon Health & Science University), Gunnar Hargus(University Hospital Münster), Susanne Höing(Max Planck Institute for Molecular Biomedicine), Yaroslav Tsytsyura(University of Münster), Michael Glatza(Max Planck Institute for Molecular Biomedicine), Marlene Klewin(Lead Discovery Center (Germany)), Susanna A. Heck(German Center for Neurodegenerative Diseases), Ashutosh Dhingra(German Center for Neurodegenerative Diseases), Olympia-Ekaterini Psathaki(Max Planck Institute for Molecular Biomedicine), Tanja Kuhlmann(University Hospital Münster), Lena F. Burbulla(German Center for Neurodegenerative Diseases), Thomas Gasser(Hertie Institute for Clinical Brain Research), David C. Schöndorf(Klinikum Ludwigshafen), Stephan A. Müller(German Center for Neurodegenerative Diseases), Hans R. Schöler(Max Planck Institute for Molecular Biomedicine), Martina Maisel(German Center for Neurodegenerative Diseases), Benjamin Schmid(German Center for Neurodegenerative Diseases), Torsten Kluba(University of Tübingen), Guangming Wu(Chinese Academy of Sciences), Cora S. Thiel(Carl Zeiss (Germany)), Heiko Müller(Lead Discovery Center (Germany)), Jürgen Klingauf(University of Münster), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Rejko Krüger(Centre Hospitalier de Luxembourg), Lydia Wagner(Max Planck Institute for Molecular Biomedicine)
Cited by 513
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k